Assorted News from the Last Week:
CAC2 Supporting Organization Member Syndax Pharmaceuticals announced that the Food and Drug Administration approved revumenib, a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
World Health Organization (WHO) has released six new target product profiles for child-friendly formulations of essential cancer medicines. You can read this recent publication for a clear, technical roadmap for pharmacy companies to develop much-needed, optimized versions of the medicines specifically designed for use in children worldwide.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects.
Study uncovers dramatic rise in childhood head and neck cancer, and girls are most at risk.
Upcoming Webinars, Online Opportunities, and Meetings:
The Science of Childhood Cancer is an interactive, weekly lecture series designed to engage the scientific community on key questions in pediatric cancer research. The Fall 2025 lecture season will run August 14 through November 20. Click here for more information and to register.
Action Days 2026 will be held in Washington, D.C. from February 24-25, 2026. Registration is open! Action Days registration will close on Friday, January 30, or when we reach 225 participants. Click here for more information and to register.
Past Recordings:
CAC2 member Phil Renna (Christina Renna Foundation) hosts an episode of At the Lab with Chris Vakoc, microbiologist and pediatric cancer researcher at Cold Spring Harbor Laboratory: “Pediatric cancers: Rare, relentless, and real”
Take Action
United Therapeutics is launching the Braving Neuroblastoma Ambassador Program. It’s designed for patients and caregivers who want to share their neuroblastoma experience in ways that feel authentic and impactful—whether that’s speaking at events, helping shape educational resources, or simply offering support to others who are just beginning their journey.
If you’d like to share your experience to help others on their journey, email Connect@BravingNB.com.
SUBSCRIBE
Sign up to receive a copy of CAC2’s free childhood cancer news digest in your inbox each week.
